{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:30:06Z","timestamp":1790760606413,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2020YFA0509400"],"award-info":[{"award-number":["2020YFA0509400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20200097"],"award-info":[{"award-number":["BK20200097"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870164 & 81372543"],"award-info":[{"award-number":["81870164 & 81372543"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Backgroud<\/jats:title>\n                <jats:p>Multiple myeloma (MM) is an incurable plasma cell malignancy in the bone marrow (BM), while immunoglobulin D type of MM (IgD MM) is a very rare but most severe subtype in all MM cases. Therefore, systemic study on IgD MM is purposeful to disclose the recurrent and refractory features in both IgD and other types of MM, and beneficial to the development of potent therapeutic strategy on MM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Agilent SBC-ceRNA microarray chips were employed to examine 3 normal plasma cell samples (NPCs), 5 lgD MM samples and 5 lgG MM samples, respectively. Sanger sequencing, RNase R digestion and qPCR assays were used to detect the existence and expression of circHNRNPU. BaseScope\u2122 RNA ISH assay was performed to test circHNRNPU levels in paraffin-embedded MM tissues. The protein encoded by circHNRNPU was identified by LC-MS\/MS, which was named as circHNRNPU_603aa. The function of circHNRNPU_603aa on cellular proliferation and cell cycle was assessed by MTT test, colony formation assay, flow cytometry and MM xenograft mouse model in vivo. RIP-seq, RIP-PCR and WB analysis for ubiquitination were performed to explore the potential mechanism of circHNRNPU_603aa in MM. Exosomes were isolated from the culture supernatant of MM cells by ultracentrifugation and characterized by Transmission Electron Microscope and WB confirmation of exosomes markers Alix and CD9.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>CircHNRNPU was one of the top most abundant and differentially expressed circRNA in IgD MM relative to lgG and NPCs samples. Increased circHNRNPU was associated with poor outcomes in four independent MM patient cohorts. Intriguingly, MM cells secreted circHNRNPU, which encoded a protein named as circHNRNPU_603aa. Overexpressed circHNRNPU_603aa promoted MM cell proliferation in vitro and in vivo, in contrast knockdown of circHNRNPU_603aa by siRNA abrogated these effects. Due to circHNRNPU_603aa including RNA-binding RGG-box region, it regulated SKP2 exon skipping, thereby competitively inhibited c-Myc ubiquitin so as to stabilize c-Myc in MM. MM cells secreted circHNRNPU through exosomes to interfere with various cells in the BM microenvironment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings demonstrate that circHNRNPU_603aa is a promising diagnostic and therapeutic marker in both MM cells and BM niche.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-022-02276-7","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T07:02:44Z","timestamp":1646722964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing"],"prefix":"10.1186","volume":"41","author":[{"given":"Xiaozhu","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinggang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"2276_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"MS Raab","year":"2009","unstructured":"Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324\u201339.","journal-title":"Lancet"},{"key":"2276_CR2","first-page":"393","volume":"322","author":"R Voelker","year":"2019","unstructured":"Voelker R. Combination approved for advanced multiple myeloma. JAMA. 2019;322:393.","journal-title":"JAMA"},{"key":"2276_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/d41573-019-00031-w","volume":"18","author":"P Wilcock","year":"2019","unstructured":"Wilcock P, Webster R. The multiple myeloma drug market. Nat Rev Drug Discov. 2019;18:579\u201380.","journal-title":"Nat Rev Drug Discov"},{"key":"2276_CR4","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015;385:2197\u2013208.","journal-title":"Lancet"},{"key":"2276_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1186\/s12885-018-4562-8","volume":"18","author":"W Wang","year":"2018","unstructured":"Wang W, Zhang C, Li Z, Gong M, Ma Y. Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma. BMC Cancer. 2018;18:650.","journal-title":"BMC Cancer"},{"key":"2276_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/annonc\/mdq393","volume":"22","author":"M Kim","year":"2011","unstructured":"Kim M, Suh C, Lee D, Min C, Kim S, Kim K, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22:411\u20136.","journal-title":"Ann Oncol"},{"key":"2276_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.bbmt.2015.02.012","volume":"21","author":"C Morris","year":"2015","unstructured":"Morris C, Iacobelli S, Gahrton G, van Biezen A, Drake M, Garderet L, et al. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1054\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2276_CR8","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3324\/haematol.2010.022848","volume":"95","author":"C Morris","year":"2010","unstructured":"Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, et al. Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 2010;95:2126\u201333.","journal-title":"Haematologica"},{"key":"2276_CR9","doi-asserted-by":"publisher","first-page":"157496","DOI":"10.1155\/2012\/157496","volume":"2012","author":"S Manier","year":"2012","unstructured":"Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012:157496.","journal-title":"J Biomed Biotechnol"},{"key":"2276_CR10","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","volume":"11","author":"C Federico","year":"2020","unstructured":"Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, et al. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nat Commun. 2020;11:6037.","journal-title":"Nat Commun"},{"key":"2276_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41571-018-0036-9","volume":"15","author":"R Xu","year":"2018","unstructured":"Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018;15:617\u201338.","journal-title":"Nat Rev Clin Oncol"},{"key":"2276_CR12","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","volume":"133","author":"E Terpos","year":"2019","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133:1534\u20139.","journal-title":"Blood"},{"key":"2276_CR13","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","volume":"129","author":"S Manier","year":"2017","unstructured":"Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017;129:2429\u201336.","journal-title":"Blood"},{"key":"2276_CR14","doi-asserted-by":"crossref","unstructured":"Shi L, Liu B, Shen D, Yan P, Zhang Y, Tian Y, Hou L, Jiang G, Zhu Y, Liang Y, et al. A tumor-suppressive circular RNA mediates uncanonical integrin degradation by the proteasome in liver cancer. Science advances. 2021;7:13.","DOI":"10.1126\/sciadv.abe5043"},{"key":"2276_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-021-01332-8","volume":"20","author":"L Wang","year":"2021","unstructured":"Wang L, Zhou Y, Jiang L, Lu L, Dai T, Li A, et al. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K\/AKT pathway. Mol Cancer. 2021;20:43.","journal-title":"Mol Cancer"},{"key":"2276_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-021-01052-y","volume":"14","author":"L Lyu","year":"2021","unstructured":"Lyu L, Zhang S, Deng Y, Wang M, Deng X, Yang S, et al. Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer. J Hematol Oncol. 2021;14:41.","journal-title":"J Hematol Oncol"},{"key":"2276_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cell.2016.03.020","volume":"165","author":"J Guarnerio","year":"2016","unstructured":"Guarnerio J, Bezzi M, Jeong JC, Paffenholz SV, Berry K, Naldini MM, et al. Oncogenic role of fusion-circRNAs derived from Cancer-associated chromosomal translocations. Cell. 2016;165:289\u2013302.","journal-title":"Cell"},{"key":"2276_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-021-01321-x","volume":"20","author":"Y Fan","year":"2021","unstructured":"Fan Y, Wang J, Jin W, Sun Y, Xu Y, Wang Y, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021;20:25.","journal-title":"Mol Cancer"},{"key":"2276_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12943-020-01199-1","volume":"19","author":"W Hu","year":"2020","unstructured":"Hu W, Liu C, Bi Z, Zhou Q, Zhang H, Li L, et al. Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology. Mol Cancer. 2020;19:102.","journal-title":"Mol Cancer"},{"key":"2276_CR20","doi-asserted-by":"crossref","unstructured":"Zhang M, Huang N, Yang X, Luo J, Zhang N. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018;37:1805-14.","DOI":"10.1038\/s41388-017-0019-9"},{"key":"2276_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-021-01358-y","volume":"20","author":"T Jiang","year":"2021","unstructured":"Jiang T, Xia Y, Lv J, Li B, Li Y, Wang S, et al. A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling. Mol Cancer. 2021;20:66.","journal-title":"Mol Cancer"},{"key":"2276_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-020-01259-6","volume":"19","author":"J Li","year":"2020","unstructured":"Li J, Ma M, Yang X, Zhang M, Luo J, Zhou H, et al. Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. Mol Cancer. 2020;19:142.","journal-title":"Mol Cancer"},{"key":"2276_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-019-1083-2","volume":"18","author":"X Xia","year":"2019","unstructured":"Xia X, Li X, Li F, Wu X, Zhang M, Zhou H, et al. Correction to: a novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1. Mol Cancer. 2019;18:149.","journal-title":"Mol Cancer"},{"key":"2276_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13059-019-1685-4","volume":"20","author":"W Liang","year":"2019","unstructured":"Liang W, Wong C, Liang P, Shi M, Cao Y, Rao S, et al. Translation of the circular RNA circ\u03b2-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 2019;20:84.","journal-title":"Genome Biol"},{"key":"2276_CR25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"2276_CR26","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543\u201353.","journal-title":"Blood"},{"key":"2276_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-020-1139-3","volume":"19","author":"H Yang","year":"2020","unstructured":"Yang H, Li X, Meng Q, Sun H, Wu S, Hu W, et al. CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer. Mol Cancer. 2020;19:13.","journal-title":"Mol Cancer"},{"key":"2276_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.taap.2018.01.015","volume":"341","author":"Y Yang","year":"2018","unstructured":"Yang Y, Guan D, Lei L, Lu J, Liu JQ, Yang G, et al. H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. Toxicol Appl Pharmacol. 2018;341:98\u2013105.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2276_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-4939-6380-5_7","volume":"1480","author":"M Gagliardi","year":"2016","unstructured":"Gagliardi M, Matarazzo MR. RIP: RNA Immunoprecipitation. Methods Mol Biol. 2016;1480:73\u201386.","journal-title":"Methods Mol Biol"},{"key":"2276_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/annonc\/mdq393","volume":"22","author":"MK Kim","year":"2011","unstructured":"Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22:411\u20136.","journal-title":"Ann Oncol"},{"key":"2276_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-019-1056-5","volume":"18","author":"X Xia","year":"2019","unstructured":"Xia X, Li X, Li F, Wu X, Zhang M, Zhou H, et al. A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1. Mol Cancer. 2019;18:131.","journal-title":"Mol Cancer"},{"key":"2276_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00412-003-0258-0","volume":"112","author":"R Helbig","year":"2003","unstructured":"Helbig R, Fackelmayer FO. Scaffold attachment factor a (SAF-A) is concentrated in inactive X chromosome territories through its RGG domain. Chromosoma. 2003;112:173\u201382.","journal-title":"Chromosoma"},{"key":"2276_CR33","doi-asserted-by":"publisher","first-page":"33384","DOI":"10.1074\/jbc.M109.021659","volume":"284","author":"K Hadian","year":"2009","unstructured":"Hadian K, Vincendeau M, Mausbacher N, Nagel D, Hauck SM, Ueffing M, et al. Identification of a heterogeneous nuclear ribonucleoprotein-recognition region in the HIV rev protein. J Biol Chem. 2009;284:33384\u201391.","journal-title":"J Biol Chem"},{"key":"2276_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/1873-3468.13943","volume":"595","author":"B Zhang","year":"2021","unstructured":"Zhang B, Wang HY, Zhao DX, Wang DX, Zeng Q, Xi JF, et al. The splicing regulatory factor hnRNPU is a novel transcriptional target of c-Myc in hepatocellular carcinoma. FEBS Lett. 2021;595:68\u201384.","journal-title":"FEBS Lett"},{"key":"2276_CR35","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/med.21675","volume":"40","author":"M Asmamaw","year":"2020","unstructured":"Asmamaw M, Liu Y, Zheng Y, Shi X, Liu H. Skp2 in the ubiquitin-proteasome system: a comprehensive review. Med Res Rev. 2020;40:1920\u201349.","journal-title":"Med Res Rev"},{"key":"2276_CR36","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S1097-2765(03)00193-X","volume":"11","author":"N von der Lehr","year":"2003","unstructured":"von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell. 2003;11:1189\u2013200.","journal-title":"Mol Cell"},{"key":"2276_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2020.01.013","volume":"67","author":"Z Cai","year":"2020","unstructured":"Cai Z, Moten A, Peng D, Hsu CC, Pan BS, Manne R, et al. The Skp2 pathway: a critical target for Cancer therapy. Semin Cancer Biol. 2020;67:16\u201333.","journal-title":"Semin Cancer Biol"},{"key":"2276_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-019-1125-9","volume":"19","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Wang W, Zhou Q, Chen C, Yuan W, Liu J, et al. Roles of circRNAs in the tumour microenvironment. Mol Cancer. 2020;19:14.","journal-title":"Mol Cancer"},{"key":"2276_CR39","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/cr.2015.82","volume":"25","author":"Y Li","year":"2015","unstructured":"Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25:981\u20134.","journal-title":"Cell Res"},{"key":"2276_CR40","doi-asserted-by":"publisher","first-page":"1703244","DOI":"10.1080\/20013078.2019.1703244","volume":"9","author":"M Catalano","year":"2020","unstructured":"Catalano M, O'Driscoll L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2020;9:1703244.","journal-title":"J Extracell Vesicles"},{"key":"2276_CR41","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","volume":"12","author":"J Bla De","year":"1994","unstructured":"Bla De J. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12:2398\u2013404.","journal-title":"J Clin Oncol"},{"key":"2276_CR42","first-page":"426","volume":"19","author":"Y Shimamoto","year":"1995","unstructured":"Shimamoto Y. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients. Cancer Detect Prev. 1995;19:426\u201335.","journal-title":"Cancer Detect Prev"},{"key":"2276_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0009-8981(93)90179-8","volume":"218","author":"S J\u00ed","year":"1993","unstructured":"J\u00ed S, Tichy M, Kov\u00e1\u0159ov\u00e1 H. Two-dimensional gel electrophoresis of four serum samples from patients with IgD myeloma. Clin Chim Acta. 1993;218:149.","journal-title":"Clin Chim Acta"},{"key":"2276_CR44","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1084\/jem.187.8.1169","volume":"187","author":"C Arpin","year":"1998","unstructured":"Arpin C, Bouteiller OD, Razanajaona D, Fugier-Vivier I, Briere F, Banchereau J, et al. The Normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene, C\u03bc\u2013C\u03b4 switch, and \u03bb light chain expression. J Exp Med. 1998;187:1169\u201378.","journal-title":"J Exp Med"},{"key":"2276_CR45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-021-01380-0","volume":"20","author":"C Gu","year":"2021","unstructured":"Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, et al. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Mol Cancer. 2021;20:84.","journal-title":"Mol Cancer"},{"key":"2276_CR46","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41392-021-00746-6","volume":"6","author":"X Tang","year":"2021","unstructured":"Tang X, Guo M, Ding P, Deng Z, Ke M, Yuan Y, et al. BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability. Signal Transduct Target Ther. 2021;6:361.","journal-title":"Signal Transduct Target Ther"},{"key":"2276_CR47","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1158\/1078-0432.CCR-19-4088","volume":"26","author":"AT Sengal","year":"2020","unstructured":"Sengal AT, Patch AM, Snell CE, Smith DS, Leung SCY, Talhouk A, et al. FGFR2c mesenchymal isoform expression is associated with poor prognosis and further refines risk stratification within endometrial Cancer molecular subtypes. Clin Cancer Res. 2020;26:4569\u201380.","journal-title":"Clin Cancer Res"},{"key":"2276_CR48","doi-asserted-by":"publisher","first-page":"107571","DOI":"10.1016\/j.celrep.2020.107571","volume":"31","author":"B Xiao","year":"2020","unstructured":"Xiao B, Zuo D, Hirukawa A, Cardiff RD, Lamb R, Sonenberg N, et al. Rheb1-independent activation of mTORC1 in mammary tumors occurs through activating mutations in mTOR. Cell Rep. 2020;31:107571.","journal-title":"Cell Rep"},{"key":"2276_CR49","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.cell.2020.08.013","volume":"182","author":"CS Cowan","year":"2020","unstructured":"Cowan CS, Renner M, De Gennaro M, Gross-Scherf B, Goldblum D, Hou Y, et al. Cell types of the human retina and its organoids at single-cell resolution. Cell. 2020;182:1623\u20131640 e1634.","journal-title":"Cell"},{"key":"2276_CR50","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2018.12.021","volume":"176","author":"JN Vo","year":"2019","unstructured":"Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The landscape of circular RNA in Cancer. Cell. 2019;176:869\u2013881 e813.","journal-title":"Cell"},{"key":"2276_CR51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1373\/clinchem.2014.230433","volume":"61","author":"J Bahn","year":"2015","unstructured":"Bahn J, Zhang Q, Li F, Chan T, Lin X, Kim Y, et al. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. Clin Chem. 2015;61:221\u201330.","journal-title":"Clin Chem"},{"key":"2276_CR52","doi-asserted-by":"publisher","first-page":"e0141214","DOI":"10.1371\/journal.pone.0141214","volume":"10","author":"S Memczak","year":"2015","unstructured":"Memczak S, Papavasileiou P, Peters O, Rajewsky N. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. Plos One. 2015;10:e0141214.","journal-title":"Plos One"},{"key":"2276_CR53","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067\u201376.","journal-title":"Blood"},{"key":"2276_CR54","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/leu.2010.320","volume":"25","author":"B Paiva","year":"2011","unstructured":"Paiva B, Perez-Andres M, Vidriales MB, Almeida J, de Las Heras N, Mateos MV, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia. 2011;25:697\u2013706.","journal-title":"Leukemia"},{"key":"2276_CR55","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bjh.12805","volume":"165","author":"A Brioli","year":"2014","unstructured":"Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol. 2014;165:441\u201354.","journal-title":"Br J Haematol"},{"key":"2276_CR56","doi-asserted-by":"crossref","unstructured":"Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, Huang N, Yang X, Zhao K, Zhou H, et al. Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. J Natl Cancer Inst. 2018;110:304-15.","DOI":"10.1093\/jnci\/djx166"},{"key":"2276_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2017.02.021","volume":"66","author":"NR Pamudurti","year":"2017","unstructured":"Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Translation of CircRNAs. Mol Cell. 2017;66:9\u201321 e27.","journal-title":"Mol Cell"},{"key":"2276_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2017.02.017","volume":"66","author":"I Legnini","year":"2017","unstructured":"Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in Myogenesis. Mol Cell. 2017;66:22\u201337 e29.","journal-title":"Mol Cell"},{"key":"2276_CR59","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9:2629.","journal-title":"Nat Commun"},{"key":"2276_CR60","doi-asserted-by":"publisher","first-page":"16435","DOI":"10.1038\/srep16435","volume":"5","author":"N Abe","year":"2015","unstructured":"Abe N, Matsumoto K, Nishihara M, Nakano Y, Shibata A, Maruyama H, et al. Rolling circle translation of circular RNA in living human cells. Sci Rep. 2015;5:16435.","journal-title":"Sci Rep"},{"key":"2276_CR61","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/cr.2017.31","volume":"27","author":"Y Yang","year":"2017","unstructured":"Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of circular RNAs driven by N (6)-methyladenosine. Cell Res. 2017;27:626\u201341.","journal-title":"Cell Res"},{"key":"2276_CR62","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1261\/rna.048272.114","volume":"21","author":"Y Wang","year":"2015","unstructured":"Wang Y, Wang Z. Efficient backsplicing produces translatable circular mRNAs. RNA. 2015;21:172\u20139.","journal-title":"RNA"},{"key":"2276_CR63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gde.2017.10.010","volume":"48","author":"AA Agrawal","year":"2018","unstructured":"Agrawal AA, Yu L, Smith PG, Buonamici S. Targeting splicing abnormalities in cancer. Curr Opin Genet Dev. 2018;48:67\u201374.","journal-title":"Curr Opin Genet Dev"},{"key":"2276_CR64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.semcdb.2014.03.016","volume":"32","author":"G Biamonti","year":"2014","unstructured":"Biamonti G, Catillo M, Pignataro D, Montecucco A, Ghigna C. The alternative splicing side of cancer. Semin Cell Dev Biol. 2014;32:30\u20136.","journal-title":"Semin Cell Dev Biol"},{"key":"2276_CR65","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1158\/0008-5472.CAN-19-0376","volume":"79","author":"S Xing","year":"2019","unstructured":"Xing S, Li Z, Ma W, He X, Shen S, Wei H, et al. DIS3L2 promotes progression of hepatocellular carcinoma via hnRNP U-mediated alternative splicing. Cancer Res. 2019;79:4923\u201336.","journal-title":"Cancer Res"},{"key":"2276_CR66","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.celrep.2017.08.012","volume":"20","author":"H Climente-Gonzalez","year":"2017","unstructured":"Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E. The functional impact of alternative splicing in Cancer. Cell Rep. 2017;20:2215\u201326.","journal-title":"Cell Rep"},{"key":"2276_CR67","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1038\/s41388-020-1345-x","volume":"39","author":"L Crawford","year":"2020","unstructured":"Crawford L, Campbell D, Morgan J, Lawson M, Down J, Chauhan D, et al. The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene. 2020;39:5001\u201314.","journal-title":"Oncogene"},{"key":"2276_CR68","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","volume":"32","author":"KK Jovanovic","year":"2018","unstructured":"Jovanovic KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S. Targeting MYC in multiple myeloma. Leukemia. 2018;32:1295\u2013306.","journal-title":"Leukemia"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02276-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02276-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02276-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T04:34:33Z","timestamp":1668141273000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02276-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2276"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02276-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in accordance with the Government-published recommendations for the Care and Use of Laboratory Animals, and were approved by the Institutional Ethics Review Boards of Nanjing University of Chinese Medicine (Ethics Registration no. 201905A003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential conflicts of interest were disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}